"Pharma firms hold billions in IP, R&D advances and patient data, making them prime targets."
Industry 4.0 brings automation and efficiency but exposes OT systems (bioreactors, DCS, SCADA) to new vulnerabilities once air-gapped.
ICS/OT malware like Industroyer, Triton and Incontroller proves attackers are targeting critical pharmaceutical infrastructure.
Compromised OT can halt production, endanger patients, and endanger staff safety.
Theft of IP and “crown jewel” data can destroy competitive advantage and invite regulatory penalties.
Malware and ransomware attacks on control and safety systems are on the rise. System obsolescence, expanded connectivity and workforce OT-awareness gaps exacerbate risks. Smart sensors and supply-chain integrations widen the attack surface rapidly.
Compromised OT can halt production, endanger patients, and endanger staff safety. Theft of IP and “crown jewel” data can destroy competitive advantage and invite regulatory penalties.
We recommend a two-phase, holistic OT risk program:
Map critical OT functions (bioreactors, chromatography), assess impact, and involve custodians and engineers to chart real-world attack paths: covering architecture, access, third-party scope, supply chain, and physical security.
Build formal policies, procedures, and playbooks aligned to: Typical elements: Governance model (RACI roles), End-to-end operating model, Regulatory compliance mapping, Asset inventory, Network diagrams, Incident response plans.
These services are best suited to address the OT risks in this industry.